Vanda Pharmaceuticals | VNDA - Operating Profit


Vanda Pharmaceuticals reported $-40.66M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
J&J USD 6.47B 1B Sep/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD 130M 945M Sep/2026
Novartis USD 1.84B 2.39B Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 4.72B 2.34B Sep/2026
Takeda JPY 205.32B 3.9B Sep/2026
Teva Pharmaceutical Industries USD 1.19B 954M Sep/2026
Ultragenyx Pharmaceutical USD -110M 35M Sep/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Veracyte USD 18.02M 5.94M Sep/2026